An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19

被引:0
作者
Jan Homolak
Ivan Kodvanj
Vladimir Trkulja
机构
[1] University of Zagreb School of Medicine,Department of Pharmacology
来源
Clinical Drug Investigation | 2021年 / 41卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:287 / 289
页数:2
相关论文
共 94 条
[1]  
Charpiat B(2020)Proton pump inhibitors are risk factors for viral infections: even for COVID-19? Clin Drug Investig. 40 897-899
[2]  
Bleyzac N(2017)Proton pump inhibitors as a risk factor for norovirus infection Epidemiol Infect. 145 1617-1623
[3]  
Tod M(2019)Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses JAMA Netw Open. 2 e1916205-624
[4]  
Prag C(2017)Acid-suppressive therapy and risk of infections: pros and cons Clin Drug Investig. 37 587-766
[5]  
Prag M(2008)Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials Can J Gastroenterol. 22 761-558
[6]  
Fredlund H(2014)Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis Gut 63 552-1086
[7]  
Vilcu A-M(2017)A review of the novel application and potential adverse effects of proton pump inhibitors Adv Ther. 34 1070-1369
[8]  
Sabatte L(2014)Gastric acid-dependent diseases: a twentieth-century revolution Dig Dis Sci. 59 1358-139
[9]  
Blanchon T(2003)A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole Nat RevDrug Discov. 2 132-684
[10]  
Souty C(2015)The physiological background behind and course of development of the first proton pump inhibitor Scand J Gastroenterol. 50 680-210